Introduction
The endoplasmic reticulum (ER) is the site where newly synthesized secretory and membrane proteins undergo structural maturation, i.e. folding, oligomeric assembly, glycosylation or formation of disulfide bonds. Consequently, the ER is the earliest compartment of the secretory pathway where proteins which have failed to mature properly can be recognized. Thus, from a teleological point of view, it is not surprising that quality control mechanisms exist in the ER which ensure that, as a rule, only correctly folded and assembled proteins are transported to the distal compartments of the secretory pathway (for review, see (Ellgaard and Helenius, 2003; Sitia and Braakman, 2003; Trombetta and Parodi, 2003) ). However, the ER is not the only compartment of the secretory pathway where quality control mechanisms are installed. As yet only poorly defined additional quality control systems have been found in the Golgi apparatus and even on the plasma membrane (for review, see (Arvan et al., 2002) ).
To prevent the ER from being obstructed by the retained proteins these have to be disposed off in a process which is now designated as ER-associated degradation (ERAD). Until 1995 it was generally accepted that the degradation of the misfolded proteins occurs inside the ER (reviewed in (Fra and Sitia, 1993) ). Since then the picture has dramatically changed leading to the current concept of ERAD which does no longer rely on proteolysis in the ER itself. After a short description of the current model of ERAD we will review the evidence for the notion that some aspects of the former concept may have been correct and that the current model of ERAD has to be broadened to reflect the different ERAD pathways.
Proteasome-dependent ERAD
The currently favored model of ERAD holds that the misfolded proteins are not degraded in the ER itself but are translocated back to the cytosol where they are degraded by the ubiquitinproteasome system (for review, see (Kostova and Wolf, 2003; McCracken and Brodsky, 2003; Tsai et al., 2002) ). Since the seminal reports on the degradation of misfolded forms of a subunit of the Sec61p complex (Sommer and Jentsch, 1993) , the cystic fibrosis transmembrane conductance regulator (Jensen et al., 1995; Ward et al., 1995) , carboxypeptidase Y (CPY*) (Hiller et al., 1996) , and pro-a-factor (Werner et al., 1996) this concept has been validated by a large number of reports on different secretory and membrane proteins in yeast as well as in mammalian cells.
Whereas some membrane proteins may be extracted from the ER membrane by the proteasome itself (Mayer et al., 1998; Walter et al., 2001 ) most membrane and all soluble proteins are 0171-9335/04/083/10-501 $30.00/0 thought to be retrotranslocated to the cytosol by a proteinconducting channel. Although final proof is still missing the core of this channel is most probably made up by the Sec61p complex (Pilon et al., 1997; Plemper et al., 1997; Plemper et al., 1998; Wiertz et al., 1996b; Zhou and Schekman, 1999) which also mediates the import of proteins into the ER. Recently, however, this view has been challenged and it has been assumed that another protein, Derlin-1, might form the retrotranslocation pore (Lilley and Ploegh, 2004; Ye et al., 2004) .
With few exceptions (Bossis et al., 2003; Rosenberg-Hasson et al., 1989; Sheaff et al., 2000; Shringarpure et al., 2002; Tarcsa et al., 2000; Werner et al., 1996) proteasomal degradation of cytosolic proteins is preceded by polyubiquitination which functions as a degradation signal for the proteasome. Polyubiquitination is mediated by the coordinated action of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) which determine the specificity of the ubiquitinproteasome system. With the exceptions of pro-a-factor (Werner et al., 1996) and amyloid b-peptide (Ab) (Schmitz et al., 2004) polyubiquitination is also required for the proteasomal degradation of ERAD substrates. Accordingly, several E2s and E3s are located at the ER membrane with their domains active in polyubiquitination facing the cytosolic side (for review, see (Jarosch et al., 2002a) ). In addition to act as a degradation signal for the proteasome, polyubiquitination may help to ensure the directionality of the retrotranslocation process by acting as a binding signal for the AAA ATPase p97/ Cdc48 which is required for retrotransloaction of several ERAD substrates (Bays et al., 2001; Braun et al., 2002; Jarosch et al., 2002b; Rabinovich et al., 2002; Ye et al., 2001) .
As in the ER lumen neither ubiquitin nor the enzymatically active domains of E2s and E3s have been detected, the polyubiquitination of soluble ERAD substrates can occur only after the protein has been retrotranslocated to the cytosol at least in part. Therefore, the specificity of ERAD may result not only from the specificity of the E2s and E3s but may be further enhanced by the specific recognition of the degradation substrates in the ER lumen prior to their retrotranslocation and polyubiquitination. In this respect, models explaining substrate recognition by proteasome-dependent and proteasome-independent ERAD face similar difficulties and will be discussed together (see below).
Proteasome-independent ERAD
The concept of proteasome-dependent ERAD stems from experiments demonstrating reduced degradation upon inactivation of the ubiquitin-proteasome system as well as from experiments reconstituting degradation from partially purified components. Reconstitution experiments provide positive evidence for the involvement of the ubiquitin-proteasome system in the degradation of a given protein but cannot exclude the existence of additional degradation mechanisms unrelated to this system. Thus, the exclusion of proteasome-independent ERAD has to rely on inhibition experiments. However, many of these experiments show a more or less clearly reduced degradation rate but not a complete abrogation of degradation. The incomplete inhibition may be due to insufficient function of the inhibitor or to redundancy of the inactivated component but it may also indicate the existence of an additional proteasomeindependent degradation pathway. Examples of such incomplete inhibition of degradation are ample including even the best characterized ERAD substrates such as CPY* (Hiller et al., 1996; Mancini et al., 2003) , cystic fibrosis transmembrane conductance regulator (Gelman et al., 2002; Jensen et al., 1995) or a1-antitrypsin (Cabral et al., 2000) .
Proteasome-independent degradation of ER-derived proteins in the cytosol
The retrotranslocation of immunoglobulin light chains (Chillaron and Haas, 2000) , CD4 (Schubert et al., 1998) , the T cell receptor subunit CD3d , a mutant form of the ABC transporter Pdr5 , and an artificial short-lived ER membrane protein (Mayer et al., 1998 ) depend on the proteolytic activity of the proteasome. Therefore, a regulatory or even mechanistic coupling of retrotranslocation and degradation has been proposed. Such a coupling argues against a cytosolic but proteasome-independent degradation of ERAD substrates.
However, examples exist which demonstrate that retrotranslocation and proteasomal degradation are not as tightly coupled. Several ERAD substrates are retained in the ER when polyubiquitination is inhibited but are found in the cytosol upon inhibition of the proteasome, e.g. major histocompatibility complex (MHC) class I heavy chain (Kikkert et al., 2001; Shamu et al., 2001; Shamu et al., 1999; Wiertz et al., 1996a; Wiertz et al., 1996b; Ye et al., 2001 ), ribophorin I (de Virgilio et al., 1998 or carboxypeptidase Y* (Biederer et al., 1997; Bordallo et al., 1998; Jarosch et al., 2002b; Ye et al., 2001 ). These findings suggest that polyubiquitination and retrotranslocation are coupled processes which are functional independent of proteasomal activity. Perhaps even more intriguing is the example of some bacterial toxins which travel in reverse through the secretory pathway to the ER from where they translocate into the cytosol. The translocation of these toxins which to a considerable extent escape proteasomal degradation (Teter et al., 2003; Wesche et al., 1999) appears to be independent of polyubiquitination, as has been shown for cholera toxin (Rodighiero et al., 2002; Schmitz et al., 2000; Winkeler et al., 2003) and ricin . Thus, at least for some proteins retrotranslocation can occur independently of the ubiquitin-proteasome system.
But is this pathway also used to deliver proteins from the ER to the cytosol for proteasome-independent degradation? A recent report on the degradation of ER-localized Ab provides evidence for such a mechanism (Schmitz et al., 2004) . Ab was shown to be exported from ER-derived microsomes independently of polyubiquitination and the proteasome. After retrotranslocation Ab is degraded by two distinct cytosolic proteolytic pathways. Whereas one fraction is degraded by the proteasome another fraction is degraded by the protease insulin-degrading enzyme. Possibly the lack of polyubiquitination renders Ab a poor substrate for the proteasome. It should be noted, however, that the proteasome is able to efficiently degrade proteins without their prior polyubiquitination, e.g. ornithine decarboxylase (Rosenberg-Hasson et al., 1989) , oxidized proteins (Shringarpure et al., 2002) or the ERAD substrate pro-a-factor (Werner et al., 1996) . Interestingly, the retrotranslocated Ab forms aggregates which contain ubiquitin and proteasomes (B¸ckig et al., 2002) . As the aggregation of Ab correlates with a conformational change from a-helix to bsheet it is conceivable that the conformation of the soluble Ab is either not recognized as ™misfolded∫ by the ubiquitin-proteasome system or that the lysine residues are buried in the molecule and not accessible to the ubiquitin ligases. A similar assumption has been made to explain how cholera toxin escapes recognition by the ubiquitin-proteasome system (Rodighiero et al., 2002) .
Ab may not be the only ERAD substrate which is degraded in the cytosol by a proteasome-independent mechanism. Lipoprotein lipase (Ben-Zeev et al., 2002) and rat nerve growth factor receptor ectodomain when expressed in yeast (Holkeri and Makarow, 1998) are degraded in a proteasome-and lysosome/vacuole-independent fashion but both are stabilized when the cellular ATP is depleted. Although neither the exact cellular compartment of their degradation nor the proteases have been identified the ATP-dependence of their degradation may indicate that the degradation of these proteins requires their retrotranslocation to the cytosol.
Although proteasomal degradation is the major source for antigenic peptides presented on MHC class I molecules cytosolic but proteasome-independent degradation may also contribute to their generation (Kloetzel and Ossendorp, 2004) . Epitopes derived from human immunodeficiency virus I ENV glycoprotein (Lopez et al., 2000) have been reported to be generated by proteasome-dependent and proteasome-independent pathways. When the expression of different alleles of human MHC class I was analyzed in the presence of proteasome inhibitors it was found that some alleles were still loaded with their respective antigens whereas others were not (Benham et al., 1998; Luckey et al., 2001) . Analysis of the inhibitorresistant antigens revealed that they included peptides derived from secretory and membrane proteins. As MHC class I loading with these peptides was TAP-dependent the peptides must have been generated in the cytosol by an apparently proteasomeindependent proteolytic system (Luckey et al., 2001) . Recently it was reported that the generation of a specific epitope derived from the human immunodeficiency virus I Nef protein was independent of proteasomal activity but was strongly reduced when tripeptidyl peptidase II (TPPII) was inhibited (Seifert et al., 2003) . It should be noted, however, that Nef protein is synthesized in the cytosol and thus may be processed differently from ER-derived proteins. TPPII is a large cytosolic subtilisinlike protease with exo-and endopeptidase activity which is upregulated upon long-term treatment with proteasome inhibitors (Geier et al., 1999) . Interestingly, by immunoelectron microscopy TPPII has been found to localize often in vicinity to the ER and Golgi apparatus (Facchinetti et al., 1999) . Whether this localization is of functional significance and whether TPPII participates in proteasome-independent ERAD remains, however, unknown.
Proteolysis in the ER
There is no doubt that several proteases are active in the ER. Signal peptides are removed from secretory and membrane proteins during their import by signal peptidase which is part of the translocon. Recently, it was found that signal peptidase is able to cleave antigenic peptides off a ricin fusion protein which was delivered to the ER by retrograde transport from the cell surface . Thus, signal peptidase may process proteins posttranslationally and independent of protein import into the ER. It has to be noted that ricin may represent a special case in that it is retrotranslocated through the translocon (Simpson et al., 1999) and thereby may come in close contact to the signal peptidase. However, the association of signal peptidase with the translocon has been reported to be transient and to depend on protein import (Kalies et al., 1998) . Thus, signal peptidase may have an additional function unrelated to its association with the translocon. Indeed, the ectodomain of human asialoglycoprotein receptor H2 is secreted after cleavage from its transmembrane domain in the ER, and signal peptidase has been implicated in this cleavage (Tolchinsky et al., 1996; Yuk and Lodish, 1993) . The uncleaved full-length H2 protein and the non-secreted fraction of the cleaved ectodomain are, however, degraded by the proteasome-dependent ERAD pathway (Ayalon-Soffer et al., 1999; KamhiNesher et al., 2001 ). Nevertheless, these findings suggest that signal peptidase may cleave not only short N-terminal peptides but can act as a true endopeptidase releasing larger protein fragments.
Signal peptidase-cleaved signal peptides are further cleaved by signal peptide peptidase, a presenilin-like aspartyl protease of the ER membrane (Weihofen et al., 2002) . This protease has as yet not been implicated in protein degradation but has been shown to be required for the release of the hepatitis C virus core protein from its precursor. The precursor is cotranslationally inserted into the ER membrane, cleaved first by signal peptidase resulting in a membrane-bound form of the core protein which is then cleaved a second time inside its transmembrane segment by signal peptide peptidase resulting in its release to the cytosol (McLauchlan et al., 2002) . Thus, signal peptide peptidase has the potential to act as an endopeptidase.
Proteases located in the Golgi apparatus may periodically return to the ER where they could contribute to protein processing or degradation. The possibility of such constitutive recycling of Golgi proteins back to the ER has been shown using a fusion protein consisting of the Golgi localization signal of the trans-Golgi protein TGN38 fused to a temperaturesensitive form of the vesicular stomatitis virus glycoprotein G. Upon recycling to the ER the fusion protein was retained there (Cole et al., 1998) . This study suggests that recycling from the Golgi to the ER could be independent of specific signals and pertain to most Golgi proteins.
This recycling pathway may explain findings implicating Golgi-™resident∫ proteases in the proteolytic processing of proteins in the ER. The a subunit of the plasma membrane metalloprotease meprin A is synthesized as an integral membrane protein and cleaved in the ER releasing the ectodomain as a soluble enzyme (Marchand et al., 1995) . This cleavage is catalyzed by furin which normally processes proproteins in the trans-Golgi network (Milhiet et al., 1995) . In accordance with this finding, furin activity has been cytochemically localized to the ER of yeast (Vorisek, 1994) .
Initiation of protein degradation by limited proteolysis in the ER
The examples reported in the preceding chapter show that limited proteolysis is occurring in the ER. Such limited proteolytic events may result in protein processing but they may also initiate protein degradation.
Signal peptidase has not only been implicated in ectodomain cleavage (see above) but also in protein degradation. A particular mutation in signal peptidase has been found to impair the turnover of a short-lived protein chimera in yeast (Mullins et al., 1995) . In this study a requirement for the proteasome, probably after the initial cleavage by signal peptidase, has, however, not been ruled out.
As with signal peptidase, furin has also been suggested not only to release ectodomains but also to initiate the degradation of proteins in the ER. Insulin receptor is normally processed by furin during its transit through the trans-Golgi network. In contrast, a misfolded form of the insulin receptor is cleaved by furin already in the ER, and this cleavage seems to be ratelimiting for further degradation of the two fragments which may occur by the proteasome (Bass et al., 2000) . How the misfolded insulin receptor activates furin which is regularly inactive in the ER is as yet unresolved.
Misfolded forms of the plasma membrane ABC transporter P-glycoprotein are degraded by the proteasome-dependent ERAD pathway (Loo and Clarke, 1998b) . For some mutations, a 130-kDa fragment accumulates upon inhibition of the proteasome. The generation of this fragment can be prevented by substituting arginine 114 which is located in the extracellular loop (Loo and Clarke, 1998a) suggesting that this fragment is generated independently of the proteasome by a distinct proteolytic cleavage in the ER lumen which may initiate the consecutive proteasomal degradation.
Protein degradation in the ER
To our knowledge, unequivocal evidence for the complete degradation (as opposed to the initiation of degradation) of misfolded proteins in the ER itself is as yet missing. Nevertheless, indirect evidence is available suggesting that protein degradation may actually occur in the ER itself.
Thyroid peroxidase (TPO) is only very inefficiently transported to the plasma membrane (Fayadat et al., 1998; Kuliawat et al., 1995; Penel et al., 1998) . Interestingly, human TPO is degraded by proteasome-dependent and -independent degradation mechanisms. Whereas unfolded TPO is degraded by the proteasome, the partially folded enzyme is degraded by an as yet unidentified serine or cysteine protease which is localized to the ER membrane (Fayadat et al., 2000) . The reason why the partially folded TPO is not degraded by the proteasome is unknown. The partial or even complete folding of a protein does not constitute a general obstacle for proteasome-dependent ERAD. The system is able to degrade folded proteins as has been shown for MHC class I heavy chain (Wiertz et al., 1996b) and is evident from the sterol-induced degradation of functional 3-hydroxy-3-methylglutaryl-CoA reductase (Hampton et al., 1996) .
Another protein which is also degraded to a large extent is apolipoprotein B (apoB). Again, evidence exists for proteasomal and non-proteasomal degradation. ApoB appears to be a special case in that it exists for prolonged periods in a partially translocated state with one portion of the protein being exposed to the ER lumen and the other to the cytosol (Davis et al., 1990; Furukawa et al., 1992; Wilkinson et al., 1992) . The structural basis for the transient translocation arrest may be the presence of pause-transfer sequences (Chuck et al., 1990) or of specific bsheet sequences (Lapierre et al., 2004; Liang et al., 1998) . As long as apoB exists in this partially translocated state it is a substrate for the proteasome-dependent ERAD (Benoist and Grand-Perret, 1997; Liang et al., 2000; Zhou et al., 1998) . Lipidation of the partially translocated apoB facilitates its complete translocation into the lumen of the ER (Chuck et al., 1990; Mitchell et al., 1998; Pariyarath et al., 2001) . After translocation has been completed apoB is still not protected from degradation but is a substrate for both, the proteasomedependent ERAD pathway (Cavallo et al., 1999; Liao et al., 1998) and less well characterized proteasome-independent degradation pathways. ApoB has been found associated with molecular chaperones even after its transport to the Golgi apparatus (Zhang and Herscovitz, 2003) suggesting that it may not reach its mature conformation in the ER which may be the reason why it is particularly prone to degradation. In several studies an about 70-kDa N-terminal fragment of apoB has been found in the ER (Adeli, 1994; Du et al., 1994) . The generation of such a large fragment is in favor of a non-proteasomal degradation because in almost all cases known so far the degradation by the proteasome is a very processive event resulting in the release of small oligopeptides. It should be noted, however, that exceptions exist which show that the proteasome is able to release larger and even biologically active proteins (Hoppe et al., 2000; Palombella et al., 1994) . Based on the susceptibility to protease inhibitors and other drugs, different proteolytic pathways have been implicated in the proteasome-independent degradation of apoB in the ER: a phenanthroline-sensitive pathway possibly involving a metalloprotease (Cartwright and Higgins, 1996; Kendrick and Higgins, 1999) , a DTT-sensitive pathway (Cavallo et al., 1999; Wu et al., 1997) , an ALLN-sensitive pathway (Wu et al., 1997) which is distinct from the proteasome (Cavallo et al., 1999 ) and a p-chloromercuribenzoate-sensitive pathway involving the ER-resident protein ER-60 (Adeli et al., 1997; Qiu et al., 2004) . Possibly the ALLN-sensitive but lactacystin-resistant pathway may also involve ER-60 because its proteolytic activity is inhibited by ALLN . ER-60 has been shown to degrade purified protein disulfide isomerase and calreticulin as well as denatured lysozyme (Otsu et al., 1995) and to interact with apoB in HepG2 liver cells (Adeli et al., 1997) . Recently, it was shown that overexpression of ER-60 results in the enhanced degradation of apoB (Qiu et al., 2004) . However, as yet formal proof is lacking that ER-60 is the protease actually degrading apoB. Alternatively, its effect on the degradation of apoB could be explained by targeting apoB for degradation by a different protease. Indeed ER-60, more commonly known as ERp57, is a member of the protein disulfide isomerase family, has been proposed to function as a molecular chaperone for glycoproteins (Elliott et al., 1997; Oliver et al., 1997) and is part of the MHC class I loading complex (Lindquist et al., 1998) . D 9 stearoyl-CoA desaturase (SCD), a key enzyme involved in the supply of mono-unsaturated fatty acids for membrane biogenesis, is a short-lived ER-resident transmembrane protein. A region in the cytosolic domain including an essential lysine residue has been identified as being responsible for the short half-life (Mziaut et al., 2000) . In spite of the cytosolic localization of the degradation signal and the requirement for the lysine residue the degradation of SCD was independent of the proteasome as shown by its independence of ATP and resistance to lactacystin (Ozols, 1997) . The SCD-degrading activity in liver microsomes was characterized as a membranebound serine protease (Heinemann et al., 2003b; Heinemann and Ozols, 1998) and later identified as plasminogen or a plasminogen-like protease (Heinemann et al., 2003a) .
Recent work in our own group has shown that a mutant form of the ER-resident molecular chaperone heavy chain binding protein (BiP) is degraded independently of the proteasome. The protease has not yet been identified but appears to be an ER-lumenal serine protease (unpublished observations).
Substrate recognition
An obvious question resulting from the presence of active proteases in the ER is how misfolded proteins are selectively recognized by these proteases. In this context, selectivity does not primarily mean the distinction of native, correctly folded and assembled proteins from misfolded ones. Native proteins are inherently more resistant against proteolysis as compared to misfolded proteins and, indeed, increased protease sensitivity is a characteristic feature of misfolded proteins unless they are heavily aggregated. Thus, the presence of limited amounts of active proteases might not endanger native proteins. In the ER, however, a major fraction of newly synthesized proteins have not yet reached their native conformations and these at least partially unfolded proteins are highly protease-sensitive. As with misfolded proteins, the enhanced sensitivity to proteases is thought to result from the exposure of regions which are buried inside the correctly folded molecule. Therefore, mechanisms must exist which protect proteins which have not yet finished their conformational maturation against premature degradation without preventing the degradation of terminally misfolded proteins. As already mentioned above, it should be pointed out that the question how terminally misfolded proteins are distinguished from folding intermediates does not only pertain to proteolytic systems active inside the ER. In principle, the same question applies to proteasomedependent ERAD because also in this degradation pathway the recognition of terminally misfolded proteins occurs, at least for soluble proteins and for the extracellular domains of transmembrane proteins, in the ER lumen.
Typically, the degradation kinetics of an ERAD substrate shows that the phase of actual degradation is preceded by a lag phase in which the amount of the protein remains constant. For glycoproteins it could be shown that during the lag phase the protein is hold in the calnexin cycle (for a recent review, see (Ellgaard and Helenius, 2003) ). Thus, confinement in the calnexin/calreticulin cycle does not only prevent export from the ER to the Golgi apparatus of folding intermediates but it also precludes degradation of the intermediates as well as of terminally misfolded proteins. Whereas a folding intermediate escapes from this cycle of repeated binding and release by proper folding, a terminally misfolded protein does not have this opportunity. Rather the cycle is interrupted by modification of the protein by a slowly acting a1,2-mannosidase I (Gonzalez et al., 1999; Hosokawa et al., 2003; Jakob et al., 1998; Liu et al., 1999) . Upon mannose-trimming the protein is recognized by ER degradation-enhancing a-mannosidase-like protein (EDEM) Jakob et al., 2001; Nakatsukasa et al., 2001) which is thought to target the protein for retrotranslocation and proteasomal degradation (Molinari et al., 2003; Oda et al., 2003) . Thus, the concerted action of rapid and efficient degradation-preventing proteins (calnexin, UDP-glucose : glycoprotein glucosyltransferase) with more slowly acting degradation-promoting proteins (a1,2-mannosidase I, EDEM) results in the preferential degradation of misfolded proteins over folding intermediates.
In a hypothetical model explaining the selectivity of proteases which are active in the ER, the degradation-promoting factors have simply be substituted by the respective protease provided the activity of the protease is rather low as compared to the degradation-preventing factors.
The calnexin cycle is not the only mechanism to protect proteins from premature degradation. BiP may have a similar function. Thus it has been reported that the half-lives of nonsecreted immunoglobulin light chains correlate with their release from BiP (Knittler et al., 1995; Knittler and Haas, 1992; Skowronek et al., 1998) . Regions of proinsulin which are located in the interior of the correctly folded and oligomerized protein were shown to be shielded by BiP in folding intermediates but not in a misfolded form of proinsulin which was degraded (Schmitz et al., 1995) . Lipoprotein lipase (LPL) forms inactive aggregates in the ER which are degraded by a degradation pathway which is resistant to the proteasome inhibitor MG-132. These aggregates show only weak interaction with molecular chaperones. When LPL-expressing cells are treated with dithiothreitol LPL forms aggregates which show a much stronger interaction with chaperones including BiP and calnexin and these aggregates are not degraded (BenZeev et al., 2002) . In mitochondria, release of a misfolded protein from the BiP homologue mtHsp70 was reported to be required for its degradation (Wagner et al., 1994) suggesting that the protection of proteins from premature degradation may be a more general function of the Hsp70 chaperone family.
Concluding remarks
To date, proteasome-dependent ERAD is by far the best characterized degradation pathway for misfolded proteins in Table 1 . Proteins potentially* degraded by proteasome-independent ERAD.
Proteasome-independent degradation after retrotranslocation Reference Ab (Schmitz et al., 2004 ) Grp94 (Luckey et al., 2001 ) HIV1 ENV-protein (Lopez et al., 2000 ) Na /K -ATPase (Luckey et al., 2001) Degradation in the ER AHDK2 (fusion of arginine permease, histidinol dehydrogenase and BiP) (Mullins et al., 1995) ApoB (Adeli et al., 1997; Cartwright and Higgins, 1996; Cavallo et al., 1999; Kendrick and Higgins, 1999; Qiu et al., 2004; Wu et al., 1997 ) Insulin receptor (Bass et al., 2000 ) P-glycoprotein (Loo and Clarke, 1998a ) SCD (Heinemann et al., 2003a; Heinemann and Ozols, 1998 ) TPO (Fayadat et al., 2000) * For several of the listed proteins evidence for non-proteasomal degradation is only circumstantial. For details, see text.
the ER. It appears to be the general mechanism by which the ER is cleared off retained misfolded proteins. Nevertheless, the examples reviewed here (Table 1 ) strongly support the notion that proteasome-dependent ERAD is not the only way the ER deals with misfolded proteins. Therefore, we would like to propose that proteasome-independent ERAD mechanisms contribute to the homeostasis of the ER (Fig. 1) . These mechanisms include proteasome-independent degradation pathways for proteins after their retrotranslocation to the cytosol as well as proteolytic systems residing in the ER itself. In addition, these ERAD pathways are supplemented by additional degradation mechanisms operating at the level of the Golgi apparatus, the plasma membrane and the endocytic system. Fig. 1 . Model of the different degradation pathways contributing to ERAD. Misfolded proteins are retained in the ER and targeted for degradation. The best-characterized and, to our current knowledge, general ERAD pathway relies on the retrotranslocation of the misfolded proteins and their consecutive degradation by the proteasome (A). However, probably due to inefficient polyubiquitination, some retrotranslocated proteins escape from proteasomal degradation and are degraded by other cytosolic proteases (B) or even completely avoid degradation, as exemplified by some bacterial and plant toxins (C). These cytosolic degradation pathways are supplemented by proteases acting in the ER itself (D).
